Swaminathan Padmanabhan (Padmanabhan) Iyer MD

Hematologic Oncology

Professor of Medicine, Dept.Lymphoma/Myeloma MD Anderson Cancer Center,

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-792-1897

Dr. Iyer is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Iyer's full profile Already have an account?

Summary

Dr. Swaminathan (Padmanabhan) Iyer is a hematologist based in Houston, TX, specializing in hematologic oncology. He completed his fellowship in Hematology and Medical Oncology at the University of Miami/Jackson Health System and has further training and an MD as a Physician Scientist from the Roswell Park Cancer Institute. He currently holds positions as an Associate Professor of Medicine at Houston Methodist Hospital and as a Staff Physician at Southwest General Hospital, among others. His areas of expertise include mycosis fungoides, Sezary syndrome, and bone marrow transplantation. Dr. Iyer has been involved in multiple clinical trials and has a strong publication record in hematologic oncology. He has received several awards, including the Clinical Care Excellence Award and the Virginia and Ernest Cockrell Presidential Award from Houston Methodist Research Institute.

Education & Training

Roswell Park Cancer InstituteMD, Physician Scientist, 2003 - 2008
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2003
Wayne State University School of MedicineResidency, Internal Medicine, 1997 - 2000
Bangalore Medical CollegeClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TX State Medical License 2008 - 2028
AZ State Medical License 2024 - 2027
GA State Medical License 2024 - 2027
LA State Medical License 2024 - 2027
MS State Medical License 2024 - 2027
OK State Medical License 2024 - 2027
TN State Medical License 2024 - 2027
WA State Medical License 2024 - 2027
AL State Medical License 2024 - 2026
MI State Medical License 2000 - 2010
NY State Medical License 2003 - 2009
FL State Medical License 2000 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Join now to see all

Awards, Honors, & Recognition

Clinical Care Excellence Award HealthNetwork, 2017, 2022-2023
CMS Meaningful Use Stage 1 Certification athenaClinicals, athenahealth, Inc., 2014, 2016
President Indo American Cancer Association

Clinical Trials

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
COMPLETED
PHASE1
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
UNKNOWN
PHASE1, PHASE2
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
UNKNOWN
PHASE1

Publications & Presentations

PubMed

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Haopeng Yang, Kotaro Arita, Kevin Bowman, Dai Chihara, Jared Henderson
Blood Cancer Discovery. 2026-09-03
Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides.
Jong Bin Park, Shamir Geller, Viviane Liao, Seda Purnak, Auris Huen
JAMA Dermatology. 2026-08-01
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Karan L Chohan, Eduardo Edelman Saul, R Eric Davis, Fredrick Hagemeister, Raphael Steiner
Blood Cancer Journal. 2026-07-02

Journal Articles

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen J, Tao W, Hao S, Iyer SP, Zu Y., Leukemia, 8/5/2015
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple...
Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC, Br J of Haematol, 8/1/2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD
Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer SP, Bradner JE, Bhalla KN, Mol Cancer Ther, 7/1/2014

Books/Book Chapters

Breast Cancer- A Practical Guide
Iyer SP et al.Editors: Silva, Orlando E. & Zurrida, Stefano.Elsevier Saunders PublishersEdition 3rd,2005

Abstracts/Posters

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Novel CD4+CD8+ Umbilical Cord Blood Regulatory T Cells
Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Houston Cell Therapy Company Launches Second-Phase Clinical TrialMay 7th, 2025
ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024
CRISPR Gene-Editing May Boost Cancer Immunotherapy, New Study FindsDecember 13th, 2022